ARTICLE | Clinical News
IL13 PE38QQR (IL13-toxin): Began Phase I testing
October 25, 1999 7:00 AM UTC
NeoPharm Inc. (NEO), Bannockburn, Ill. Product: IL13 PE38QQR (IL13-toxin) Business: Cancer Therapeutic category: Cytotoxic Target: IL-13 receptor on cancer cells Description: Ligand-targeted bacterial...